{"product_id":"theoncologyinstitute-five-forces-analysis","title":"The Oncology Institute Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThe Oncology Institute faces intense provider rivalry and significant buyer scrutiny, while supplier leverage and regulatory pressures shape treatment costs and access; emerging biotech advances and alternative care models pose notable substitute and entrant threats. This snapshot teases core dynamics—unlock the full Porter's Five Forces Analysis to access force-by-force ratings, visuals, and strategic implications tailored to The Oncology Institute.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Manufacturer Dominance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe oncology sector depends on high-cost biologics and specialty chemotherapies made by a few global pharma giants, giving suppliers strong pricing power tied to patents and life-saving status. By end-2025, global oncology drug sales hit about $200 billion, with precision medicines growing ~10% annually, boosting supplier leverage over community practices like The Oncology Institute. Manufacturer consolidation and limited biosimilar uptake keep average oncology drug prices high, raising procurement costs and margin pressure. This shifts bargaining power firmly toward suppliers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Medical Labor Shortage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe supply of board-certified oncologists, hematologists, and specialized oncology nurses remains constrained versus a 28% rise in US cancer survivors from 2000–2022, keeping vacancy rates for oncology roles near 8–10% in 2024; this scarcity lets clinicians demand 10–25% higher pay and richer benefits, pushing community clinic labor costs up materially. Recruitment and retention strategies—signing bonuses, loan repayment, telemedicine, and flexible schedules—are critical as the labor market for highly skilled clinical staff stays extremely tight through 2025, with projected shortfalls of several thousand specialists nationwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Diagnostic Equipment Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers of radiation oncology machines and advanced imaging hold strong leverage because machines cost $2–10M each and require proprietary service contracts; global market share is concentrated—Varian\/Siemens\/Philips and Elekta account for over 70% of installed bases as of 2025.\u003c\/p\u003e\n\u003cp\u003eThat concentration limits The Oncology Institute’s price and service negotiation, with annual maintenance often 8–12% of equipment cost and multi-year spare-part lead times.\u003c\/p\u003e\n\u003cp\u003eThe Institute must keep strategic vendor ties and budget ~5–8% of annual capital spend for upgrades to secure access to new AI-guided imaging and HDR radiotherapy tech.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGroup Purchasing Organization Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGPOs aggregate hospital and clinic demand to cut drug prices but also control formularies and vendor access, shaping which oncology drugs The Oncology Institute can buy; in 2024 GPO-contracted rebates accounted for ~18–25% off list prices in oncology portfolios, directly affecting margins.\u003c\/p\u003e\n\u003cp\u003eThe Institute depends on GPO agreements for 40–60% of its infused drug spend volume discounts, so renegotiation or rebate clawbacks—seen in 2023–24 when two major GPOs trimmed oncology rebates by ~3–5%—can reduce net margin and raise patient cost-share.\u003c\/p\u003e\n\u003cp\u003eThe risk: a shift in GPO contracts, consolidation among three dominant GPOs controlling ~70% of US non-federal healthcare purchasing, or changes in manufacturer rebate structures can quickly increase drug cost per treatment episode and compress operating income.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGPOs deliver 18–25% average oncology rebates\u003c\/li\u003e\n\u003cli\u003eThree GPOs ≈70% market share\u003c\/li\u003e\n\u003cli\u003eInstitute relies on GPOs for 40–60% volume discounts\u003c\/li\u003e\n\u003cli\u003e2023–24 rebate cuts ~3–5% hit margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData and Technology Vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe Oncology Institute depends on specialized EHRs and AI clinical decision support, giving vendors strong leverage as of 2025 when 78% of US oncology centers report AI use in workflows (ASCO 2025); vendor pricing and feature roadmaps directly affect care costs and outcomes.\u003c\/p\u003e\n\u003cp\u003eSwitching costs are very high: median EHR migration for large oncology practices runs $1.2–$3.5M and 9–14 months of retraining, so providers face data-migration risk and operational downtime.\u003c\/p\u003e\n\u003cp\u003eAs oncology shifts further data-driven by late 2025, tech partners become essential but demanding suppliers, able to extract higher margins via proprietary integrations and recurring SaaS fees (typical gross margins 60–75% in health IT).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e78% oncology centers using AI (ASCO 2025)\u003c\/li\u003e\n\u003cli\u003eMigration cost $1.2–$3.5M, 9–14 months retraining\u003c\/li\u003e\n\u003cli\u003eHealth IT gross margins 60–75%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier Power Compresses Margins: GPOs, Biologics \u0026amp; EHR Costs Strain Institute\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold strong power: concentrated drug makers, pricey biologics (~$200B oncology sales 2025; precision +10%\/yr), GPOs (3 firms ≈70% share) and costly equipment\/EHR vendors push prices and margins; Institute relies on GPOs for 40–60% discounts and faces $1.2–$3.5M EHR swap costs, 8–10% clinician vacancy-driven wage pressure, and 8–12% annual equipment maintenance.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology sales 2025\u003c\/td\u003e\n\u003ctd\u003e$200B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO share\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO rebates\u003c\/td\u003e\n\u003ctd\u003e18–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEHR migration\u003c\/td\u003e\n\u003ctd\u003e$1.2–$3.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for The Oncology Institute, this Porter's Five Forces analysis uncovers key drivers of competition, buyer and supplier power, entry barriers, substitutes, and disruptive threats to its market position, with strategic insights for investors and management.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCompact Porter's Five Forces snapshot tailored for The Oncology Institute—quickly pinpoint competitive pressures and strategic pain points for faster, board-ready decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Private Payors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cplarge commercial insurers cover about of us oncology patients medicare aside a few payors negotiate rates that set regional benchmarks. these pressure providers via narrow networks and bundled payments care model expanded interest per-case revenues by an estimated versus fee-for-service. the institute must secure favorable contracts outcomes data to keep market access protect margins.\u003e\n\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Payor Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedicare and Medicaid cover roughly 55% of oncology patients, making the Centers for Medicare and Medicaid Services (CMS) the dominant buyer and price setter for The Oncology Institute.\u003c\/p\u003e\n\u003cp\u003eCMS shifts to value-based care and revisions to the Physician Fee Schedule directly cut practice revenue; a 2024 CMS rule reduced certain infusion payments by ~4–6% for community clinics.\u003c\/p\u003e\n\u003cp\u003eBy late 2025, mandatory alternative payment models (APMs) expanded, forcing providers to show cost-efficiency or face reimbursement penalties, raising margin pressure across oncology practices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Empowerment and Choice\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising healthcare transparency and price tools mean patients compare outcomes, costs, and convenience; 2024 survey data show 62% of cancer patients shop providers, boosting bargaining power.\u003c\/p\u003e\n\u003cp\u003eThe Oncology Institute’s community model—400+ clinics nationally as of 2025—wins patients wanting care near home, yet 28% still choose academic centers for complex cases.\u003c\/p\u003e\n\u003cp\u003eWith 35% of commercially insured US adults in high-deductible plans (2024), cost-conscious patients push for high-value, lower-cost outpatient oncology, strengthening customer influence on site of care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmployer-Led Health Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLarge employers like Amazon and Walmart contracted direct cancer care deals in 2024, pushing oncology providers to negotiate bundled pricing; employers aim to cut total cost of care by 10–30% while keeping high-quality access to speed return-to-work.\u003c\/p\u003e\n\u003cp\u003eOncology practices now must show outcomes and ROI—e.g., 2023 employer health surveys report 42% of benefits directors expect value-based oncology contracts within 2 years—pressuring margins and requiring robust real-world evidence.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect contracts rising: major employers piloting bundled oncology since 2023\u003c\/li\u003e\n\u003cli\u003eCost targets: employers seek 10–30% TCOC reductions\u003c\/li\u003e\n\u003cli\u003eMetrics demanded: survival, time-to-return-to-work, total episode cost\u003c\/li\u003e\n\u003cli\u003eImpact: higher administrative burden, price transparency, margin pressure\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReferral Source Leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePrimary care physicians and general surgeons are gatekeepers whose referral shifts can cut an oncology practice’s patient volume by 10–25% within 6–12 months, per 2024 oncology referral studies showing 18% average yearly referral concentration.\u003c\/p\u003e\n\u003cp\u003eMaintaining strong networks, publishing 12‑month survival and patient‑satisfaction metrics, and sharing 30% better outcomes in specific tumor streams reduces referral attrition risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGatekeepers: PCPs \u0026amp; surgeons\u003c\/li\u003e\n\u003cli\u003eVolume risk: 10–25% drop in 6–12 months\u003c\/li\u003e\n\u003cli\u003eReferral concentration: ~18% yearly\u003c\/li\u003e\n\u003cli\u003eMitigation: networks, outcomes, satisfaction\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers squeeze margins—insurers, CMS, employers and patients force cuts; lock outcomes \u0026amp; networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers have high power: insurers (60–70% commercial), CMS (~55% coverage), employers and price‑shopping patients (62% shop) push value and bundled payments, cutting revenues 4–15%; referrals concentrate volume (18% yearly), so The Oncology Institute must secure contracts, outcomes data, and local networks to protect margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial insurers\u003c\/td\u003e\n\u003ctd\u003e60–70%\u003c\/td\u003e\n\u003ctd\u003e-5–15% revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMS\u003c\/td\u003e\n\u003ctd\u003e~55%\u003c\/td\u003e\n\u003ctd\u003epayment cuts 4–6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003e62% shop\u003c\/td\u003e\n\u003ctd\u003esite‑of‑care shift\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eThe Oncology Institute Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Porter’s Five Forces analysis of The Oncology Institute you'll receive immediately after purchase—no placeholders or samples. The document is fully formatted, professionally written, and ready for download and use the moment you buy. What you see here is the complete deliverable, available for instant access with no further setup or customization required.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747357962617,"sku":"theoncologyinstitute-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/theoncologyinstitute-five-forces-analysis.png?v=1772197689","url":"https:\/\/growthsharematrix.com\/products\/theoncologyinstitute-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}